(Q42937932)

11 November 2017

HDAC inhibitors and their potential applications to glioblastoma therapy (English)

1 reference

11 November 2017

1 reference

Eleni Adamopoulou

1

1 reference

PMC publication ID

3805657

11 November 2017

Ulrike Naumann

series ordinal

2

1 reference

11 November 2017

10 June 2013

1 reference

11 November 2017

1 reference

11 November 2017

2

1 reference

11 November 2017

8

1 reference

11 November 2017

e25219

1 reference

Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells

11 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805657

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805657

The biology of HDAC in cancer: the nuclear and epigenetic components

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805657

Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805657

The role of histone deacetylases (HDACs) in human cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805657

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805657

TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805657

MICA/NKG2D-mediated immunogene therapy of experimental gliomas.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805657

The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805657

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805657

16 August 2018

Identifiers

DOI

10.4161/ONCI.25219

1 reference

11 November 2017

1 reference

PMC publication ID

3805657

11 November 2017

PubMed publication ID

24167760

1 reference

PMC publication ID

3805657